

September 7, 2015

Commencement of T cell receptor (TCR) and B cell receptor (BCR) analysis business
(follow-up report)

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that OncoTherapy has been applying a T cell receptor (TCR) analysis method to OncoTherapy’s vaccine development and also has begun TCR (and BCR) analysis service to customers including pharmaceutical companies and academic institutions.

mRNA-based TCR analysis method using the next-generation sequencer (*) was developed by Professor Yusuke Nakamura’s laboratory at Department of Medicine, the University of Chicago, as a leading-edge approach to cancer immunotherapy, which can monitor changes in T cells in blood, cancer tissues, ascites and pleural effusion, and rapidly provide the information of TCRs (BCRs) from a few to more than ten million T (B) cells. The method is also applicable to various disease conditions including autoimmune diseases, drug hypersensitivity, food allergies and infections.

OncoTherapy, in collaboration with the University of Chicago, will apply world’s most advanced TCR analysis techniques to selecting patients for immunotherapy including vaccine therapies and monitoring immune responses during the course of treatment. We will also conduct the research and development of the TCR (BCR) analysis and its commercialization to contribute to medicine.

(*) Methods for studying characteristics of T cells (or B cells) by determining DNA sequences of T cell receptors (or B cell receptors) that recognize antigens.